Trial
NCT01798485
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Synta Pharmaceuticals Corp.
Collaborators
—
Condition
Non-Small-Cell Lung Adenocarcinoma
Intervention
Docetaxel
Why stopped
The study was stopped after the first Interim Analysis due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-01